FROM PUBLIC EVENTS · 2026-11-15

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Late clinical · capacity Raising output substantially with a new eye-drop building at its Ansan plant.

  • Decision to invest in a new eye-drop building at the Ansan plant. Source

Roles often seen at this stageManufacturing & MSAT · Quality QA & QC · Clinical & PV

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-15

Kukje Pharma

A prescription-drug maker centred on ophthalmic medicines such as eye drops, developing a combination glaucoma eye drop.

Idenzelt

Marketed

Retinal-disease treatment whose sales passed about KRW 14 billion within a year of launch.

Announced

Decided to invest KRW 55.5 billion in a new eye-drop building at its Ansan plant, raising eye-drop output by 133%.

Official role guide

Kukje Pharma careers

Current availability unconfirmed

Observed 2026-11-15

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 3

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 국제약품, 가동률 130% 안산공장 증설…점안제 생산 늘린다 ↗비즈워치 · Published 2026-08-24 · Sources checked 2026-11-15 · Original unavailable
  2. 국제약품, 창립 67주년…555억원 점안제 공장 신축 추진 ↗메디파나뉴스 · Published Date unconfirmed · Sources checked 2026-11-15 · Original unavailable
  3. 국제약품·셀트리온제약 "안과 약, 1년 만에 140억 돌파" ↗뉴시스 · Published 2026-02-24 · Sources checked 2026-11-15 · Original unavailable